ProMIS Neurosciences
Most recent annual filing: 2026-03-25
- PMN310 filing2H 2026PMN310 filing, 2H 2026, notable
- PMN310 corporate update2H 2026PMN310 corporate update, 2H 2026, routine
- Sabirnetug Ph2 toplinelate 2026Sabirnetug Ph2 topline, late 2026, thesis-defining
- PMN310 topline1Q 2027PMN310 topline, 1Q 2027, thesis-defining
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (6 active programs)
Technology platforms
EpiSelect · University of British Columbia
Computational discovery platform using thermodynamics and statistical mechanics to model protein misfolding and identify disease-specific conformational epitopes on toxic misfolded proteins. Used to generate selective monoclonal antibodies, intrabodies, and therapeutic vaccines targeting neurodegenerative and misfolded protein diseases including Alzheimer's disease, ALS, Parkinson's disease, MSA, DLB, frontotemporal dementia, and schizophrenia.
Targets: amyloid beta oligomers, alpha-synuclein, TDP-43, tau, SOD1, RACK1, DISC1
EpiSelect
Computational platform to identify conformational epitopes uniquely exposed on toxic misfolded proteins, used to generate misfolding-specific antibodies or vaccine formulations targeting neurodegenerative diseases including Alzheimer's disease, ALS, FTD, Parkinson's disease, and multiple system atrophy.
Biotech Distilled coverage (3)
- 2026-07-28 UPDATE: ProMIS Neurosciences (PMN) - The Interim Gets a Date 🔒 Paid
- 2026-07-28 UPDATE: ProMIS Neurosciences (PMN) - The Low-Information Print That Wasn’t 🔒 Paid
- 2026-07-07 ProMIS Neurosciences (PMN) — Scientific Deep Dive for PMN310 and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.